HC Wainwright Expects Increased Earnings for Gossamer Bio

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Research analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of Gossamer Bio in a research report issued on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.15) for the quarter, up from their prior forecast of ($0.17). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Gossamer Bio's Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.50) EPS, Q1 2026 earnings at ($0.09) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.17) EPS.

GOSS has been the subject of a number of other research reports. The Goldman Sachs Group upped their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Friday, May 16th. Wedbush reissued an "outperform" rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, May 16th.

Gossamer Bio Trading Down 6.7%

Shares of NASDAQ GOSS traded down $0.08 on Monday, reaching $1.12. 1,186,654 shares of the company traded hands, compared to its average volume of 1,548,869. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.55. The company has a 50 day moving average of $1.01 and a 200 day moving average of $1.00. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The stock has a market capitalization of $254.58 million, a PE ratio of -3.50 and a beta of 1.82.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. The firm had revenue of $9.89 million during the quarter, compared to analyst estimates of $3.95 million.

Institutional Trading of Gossamer Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Graham Capital Management L.P. purchased a new position in Gossamer Bio in the 4th quarter worth approximately $32,000. Virtu Financial LLC purchased a new position in Gossamer Bio in the 1st quarter worth approximately $38,000. Fullcircle Wealth LLC purchased a new position in Gossamer Bio in the 4th quarter worth approximately $43,000. Invesco Ltd. purchased a new position in Gossamer Bio in the 1st quarter worth approximately $48,000. Finally, Velan Capital Investment Management LP purchased a new position in Gossamer Bio in the 4th quarter worth approximately $68,000. Institutional investors and hedge funds own 81.23% of the company's stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.